# Beijing Centre Biology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beijing-centre-biology-co

- Industry: Pharmaceuticals
- Headquarters: Beijing, China
- Website: www.centreherbs.com
- Total disclosed funding: $22M
- Latest round: Series C (Jun 18, 2015)
- Investors on record: 4

## About

Beijing Centre Biology Co., Ltd is a specialized manufacturer focusing on natural health products, particularly Astragalus polysaccharide powder, serving both domestic and international markets with a commitment to quality.Beijing Centre Biology Co., Ltd operates in the health supplement sector, specializing in the production of Astragalus polysaccharide powder, the only company in the industry licensed to manufacture this product. Founded in Beijing, China, the company's CEO is Housheng Jiang. In June 2015, the firm raised CNY 40 million in Series C funding from Lyfe Capital and Tengye Ventures, which represents the total amount raised to date. The company has completed three funding rounds, with the latest deal occurring on June 18, 2015.Beijing Centre Biology Co., Ltd specializes in producing Astragalus polysaccharide powder, which is derived from the Astragalus plant, recognized for its potential health benefits, including immune support and anti-inflammatory properties. The company's primary offerings cater to various industries, notably dietary supplements and functional foods, addressing the needs of health-conscious consumers and businesses globally. Their products are distributed across Asia, Europe, and North America, ensuring compliance with regulatory standards and focusing on quality to meet market demands.Beijing Centre Biology Co., Ltd generates revenue through direct sales of its flagship Astragalus polysaccharide powder to clients in the health supplement and natural food sectors. The sales process is conducted on a B2B basis, with bulk order placements structured around contractual agreements. The company collaborates with retailers and wholesalers to distribute its products, facilitating consistent sales through recurring orders and long-term contracts, driven by the growing demand for natural health products in global markets.Looking ahead, Beijing Centre Biology Co., Ltd plans to utilize the CNY 40 million raised in Series C funding to enhance its product offerings, including the launch of new health supplements derived from Astragalus polysaccharide. The company aims to expand its market presence into North America and Europe by the end of 2016, capitalizing on trends in natural health solutions. Additionally, they are exploring entry into the Southeast Asian market to meet increasing consumer demand for natural products.

## Funding rounds

- Series C, Jun 18, 2015, $6.5M — LYFE Capital, Tengye Ventures
- Series B, Jul 1, 2012, $7.9M — Qiming Venture Partners, Cowin Capital
- Series A, Sep 1, 2011, $7.8M — Qiming Venture Partners

## Investors

- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A, Series B
- Cowin Capital (https://capitalatlas.ai/funds/cowin-capital) — Series B
- LYFE Capital — Series C
- Tengye Ventures (https://capitalatlas.ai/funds/tengye-ventures) — Series C